3. >>Regulation

Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test

CMS opened a national coverage determination for Exact Sciences Cologuard, the first stool-based colorectal cancer screening test on the same day FDA approved the test. This is the first simultaneous approval/coverage determination under FDA and CMS’ joint parallel review program.

FDA’s approval of Exact Sciences Corp.’s PMA for the Cologuard stool-based colorectal screening teston August 11, the same day CMS proposed national coverage for the unique non-invasive cancer test, marks an important milestone for the agencies’ parallel-review program.

Cologuard is the first product to complete parallel FDA-CMS review under the pilot parallel review program, a voluntarily pilot open...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation